Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $2M of Stock

Qiming Corporate GP VI, Ltd. sold 75,508 shares of Alamar Biosciences, Inc. (NasdaqGS: ALMR) on October 19, 2026. The Form 4 filing with the SEC shows the 10% owner executed the transaction at a price of $26.34 per share, totaling about $1.99 million. This transaction follows an earlier sale by the same owner on October 15, 2026.

ALMR Alamar Biosciences, Inc.

$28.16 ▲ +17.73% past 3 months

1M 3M

Daily close · Oct 20, 2026

Inside Qiming Corporate GP VI's Alamar Biosciences Trade

The sale reduced the institutional investor's stake by about 3.9%, leaving it with 1,877,116 shares. Alamar Biosciences shares closed at $26.30 on the day of the trade. The transaction was not executed under a pre-arranged Rule 10b5-1 trading plan.

Other Institutional Activity in Alamar Biosciences

Other large funds actively adjusted their positions in the proteomics company earlier in the year. Sands Capital Alternatives, LLC grew its holdings by 2,115,463 shares, ending with 4,230,926 shares worth about $133.1 million. Samsara BioCapital, LLC added 1,240,155 shares, finishing with 2,480,310 shares valued at roughly $78.0 million. ARK Investment Management, LLC grew its stake by 686,980 shares to reach 1,373,959 shares worth about $43.2 million. Braidwell LP lifted its position by 541,992 shares, holding 1,083,983 shares valued at approximately $34.1 million. Alliancebernstein L.P. grew its holdings by 501,538 shares, ending with 1,003,077 shares worth about $31.5 million.

Alamar Biosciences, Inc. Stock Up 11.7%

Alamar Biosciences shares recently traded around $31.45 as of October 22, 2026, sitting up about 19.6% since the trade date. The stock trades above its 50-day moving average of $31.01 and above its 200-day moving average of $26.63. The shares trade below their 52-week high of $39.61 and above their 52-week low of $18.85.

Recent Earnings

Alamar Biosciences generated $100.4 million in trailing twelve-month revenue with an 82.1% year-over-year revenue growth rate. The company posted a net profit margin of -49.5% and earnings per share of -$1.20 over the same period. The company's next earnings report is scheduled for November 3, 2026, after the market close. The firm holds a current ratio of 11.85 and a quick ratio of 9.67, alongside a debt-to-equity ratio of 16.43.

Insider Buying and Selling at Alamar Biosciences, Inc.

Insider activity prior to this sale included Director Nicholas J. Naclerio purchasing 235,294 shares at $22.00 on April 20, 2026, for roughly $5.2 million. Beneficial owner Illumina Innovation Fund II Gp also bought 235,294 shares at $22.00 on the same date for about $5.2 million. Qiming Corporate GP VI, Ltd. previously sold 173,537 shares at an average price of $27.73 on October 15, 2026, worth approximately $4.8 million.

Analysts Set New Price Targets

Stifel maintained a buy rating on the stock while raising its price target to $32.00 from $28.00 on August 11, 2026. JP Morgan maintained an overweight rating on August 11, 2026, while lifting its price target to $35.00 from $32.00. The stock currently holds a consensus buy recommendation from five analysts, with a target high price of $45.00 and a target low price of $31.00.

About Alamar Biosciences

Alamar Biosciences, Inc. operates as a proteomics company headquartered in Fremont, California. The firm develops a proteomic liquid biopsy platform and sells instruments, consumables, and services for the early detection of diseases. Its proprietary NULISA technology functions as a proteomics platform designed to detect and quantify protein biomarkers.

Bottom Line

Investors will watch the upcoming earnings release on November 3, 2026, for updates on revenue growth and cash burn. Further SEC filings will show whether Qiming Corporate GP VI continues to trim its position.